Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Melanotan II: Evidence Summary
Evidence summary for Melanotan II across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Melanotan II overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Sexual dysfunction (erectile) | Tier C | 3 | MC4R activation produces erectogenic effects; some clinical evidence in ED patients |
| Skin tanning | Tier D | 2 | Increases melanogenesis but safety concerns limit clinical utility; not approved |
References (5)
- Melanoma associated with the use of melanotan-II. . Dermatology (Basel, Switzerland) (2014) PMID: 24355990
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. . Clinical toxicology (Philadelphia, Pa.) (2012) PMID: 23121206
- Interdisciplinary and interprofessional communication intervention: How psychological safety fosters communication and increases patient safety. . Frontiers in psychology (2023) PMID: 37397302
- Melatonin and alcohol-related disorders. . Chronobiology international (2020) PMID: 32419511
- Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. . CNS neuroscience & therapeutics (2009) PMID: 19228178